<DOC>
	<DOCNO>NCT02606097</DOCNO>
	<brief_summary>The main purpose study examine whether regorafenib treatment help people gastrointestinal stromal tumour ( GIST ) gene mutation c-kit exon 17 . The safety regorafenib treatment also examine .</brief_summary>
	<brief_title>Regorafenib GIST With Secondary C-KIT Exon 17 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>An eligible subject must fulfill follow inclusion criterion : Signed informed consent ( IC ) obtain study specific procedure . Patients must able understand willing sign write IC . Pathologically confirm gastrointestinal stromal tumour . All patient receive imatinib sunitinib . Pathological confirm ckit exon 17 mutation . At least one measurable lesion nonirradiated area allow track whether circumstance recurrence compute tomography ( CT ) magnetic resonance imaging ( MRI ) . Aged &gt; 20 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy great 12 week . Adequate bone marrow function : 1 ) Absolutely neutrophil count &gt; = 1.5 x10^9/L white blood cell count ( WBC ) &gt; = 4x10^9/L ; 2 ) Hemoglobin &gt; = 9 g/dL ; 3 ) Platelet count &gt; = 100x10^9/L . Adequate liver function : 1 ) Total bilirubin &lt; = 1.5x upper limit normal ( ULN ) ; 2 ) Alanine Aminotransferase ( ALT ) &amp; Aspartate Aminotransferase ( AST ) &lt; = 2.5x ULN without liver metastasis &lt; = 5x ULN hepatic metastasis ; 3 ) Alkaline phosphatase &lt; = 2.5x ULN without liver metastasis &lt; = 5x ULN hepatic metastasis bone metastasis ; 4 ) Bilirubin &lt; 2x ULN . Adequate renal function : creatinine &lt; 1.5x ULN . Patients must accessible treatment followup participate center . Subject meet follow exclusion criterion : Major surgery within four week prior enter study . Patients central nervous system ( CNS ) metastasis , include clinical suspicion . Patients active uncontrolled infection . Patients unstable angina ( angina symptom rest , newonset angina ( begin within last 3 month ) myocardial infarction history 6 month entry . Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) . Congestive heart failure New York Heart Association ( NYHA ) class 2 . Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication . Patients pregnant breast feeding . Other concomitant previously malignancy within 5 year except situ cervix cancer squamous cell carcinoma skin treat surgery . Mental status fit clinical trial . Can take study medication orally . Fertile men woman unless use reliable appropriate contraceptive method . Patients evidence history bleed diathesis , irrespective severity . Any hemorrhage bleeding event &gt; = Common Terminology Criteria Adverse Events ( CTCAE ) Grade 3 within 4 week prior start study medication . Nonhealing wound , ulcer , bone fracture . Renal failure require hemoor peritoneal dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>